Log in

NASDAQ:ADRO - Aduro BioTech Stock Price, Forecast & News

$1.12
-0.06 (-5.08 %)
(As of 12/15/2019 04:00 PM ET)
Today's Range
$1.11
Now: $1.12
$1.20
50-Day Range
$0.91
MA: $1.11
$1.22
52-Week Range
$0.90
Now: $1.12
$4.59
Volume791,630 shs
Average Volume709,753 shs
Market Capitalization$90.17 million
P/E RatioN/A
Dividend YieldN/A
Beta1.49
Aduro BioTech, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADRO
CUSIPN/A
Phone510-848-4400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.09 million
Book Value$1.70 per share

Profitability

Net Income$-95,360,000.00
Net Margins-544.94%

Miscellaneous

Employees152
Market Cap$90.17 million
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive ADRO News and Ratings via Email

Sign-up to receive the latest news and ratings for ADRO and its competitors with MarketBeat's FREE daily newsletter.


Aduro BioTech (NASDAQ:ADRO) Frequently Asked Questions

What is Aduro BioTech's stock symbol?

Aduro BioTech trades on the NASDAQ under the ticker symbol "ADRO."

How were Aduro BioTech's earnings last quarter?

Aduro BioTech Inc (NASDAQ:ADRO) announced its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.23) by $0.03. The biotechnology company had revenue of $4.80 million for the quarter, compared to analyst estimates of $4.55 million. Aduro BioTech had a negative net margin of 544.94% and a negative return on equity of 78.64%. View Aduro BioTech's Earnings History.

When is Aduro BioTech's next earnings date?

Aduro BioTech is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Aduro BioTech.

What price target have analysts set for ADRO?

6 brokers have issued twelve-month price objectives for Aduro BioTech's stock. Their forecasts range from $8.30 to $9.00. On average, they anticipate Aduro BioTech's share price to reach $8.65 in the next twelve months. This suggests a possible upside of 672.3% from the stock's current price. View Analyst Price Targets for Aduro BioTech.

What is the consensus analysts' recommendation for Aduro BioTech?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aduro BioTech in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aduro BioTech.

What are Wall Street analysts saying about Aduro BioTech stock?

Here are some recent quotes from research analysts about Aduro BioTech stock:
  • 1. According to Zacks Investment Research, "Aduro's three distinct technology platforms are being utilized by several companies to develop treatments for several cancer indications. The company’s collaboration agreements with large pharma companies — Novartis and Johnson & Johnson — not only validate its research platforms but also enhance its financial position, providing it with adequate funds. However, with no approved products in Aduro’s portfolio, the company heavily depends on funds generated from collaboration and license agreements, government grants as well as other payments for the development of its pipeline candidates. Thus, an inability to secure sufficient funding could hinder Aduro’s pipeline progress. Shares of the company have outperformed the industry so far this year. Loss estimates look stable ahead of Q1 earnings. Aduro has a positive record of earnings surprises in the recent quarters." (5/7/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating, and $8.30 price target. Our target is based on our clinical net present value (NPV) model, which derives value from across Aduro’s assets but primarily for ADU-S100. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (12/19/2018)

Has Aduro BioTech been receiving favorable news coverage?

News headlines about ADRO stock have been trending somewhat negative on Sunday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aduro BioTech earned a news impact score of -1.9 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Aduro BioTech.

Are investors shorting Aduro BioTech?

Aduro BioTech saw a increase in short interest in November. As of November 15th, there was short interest totalling 1,700,000 shares, an increase of 23.2% from the October 31st total of 1,380,000 shares. Based on an average trading volume of 595,000 shares, the short-interest ratio is presently 2.9 days. Approximately 3.4% of the shares of the company are short sold. View Aduro BioTech's Current Options Chain.

Who are some of Aduro BioTech's key competitors?

What other stocks do shareholders of Aduro BioTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aduro BioTech investors own include EXACT Sciences (EXAS), Regulus Therapeutics (RGLS), Flexion Therapeutics (FLXN), Juno Therapeutics (JUNO), Paratek Pharmaceuticals (PRTK), PTC Therapeutics (PTCT), MDxHealth (MXDHF), CareDx (CDNA), Alibaba Group (BABA) and Cerus (CERS).

Who are Aduro BioTech's key executives?

Aduro BioTech's management team includes the folowing people:
  • Mr. Stephen T. Isaacs, Chairman, CEO & Pres (Age 70)
  • Dr. Andrea van Elsas, Chief Scientific Officer (Age 52)
  • Mr. Blaine E. Templeman, Chief Admin. Officer & Chief Legal Officer (Age 53)
  • Ms. Jennifer Lew, Chief Financial Officer (Age 46)
  • Ms. Alexandra Santos, Exec. Director of Corp. Affairs & Investor Relations

When did Aduro BioTech IPO?

(ADRO) raised $119 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 7,000,000 shares at a price of $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Who are Aduro BioTech's major shareholders?

Aduro BioTech's stock is owned by many different of institutional and retail investors. Top institutional investors include State Street Corp (1.60%), Assenagon Asset Management S.A. (0.53%), Millennium Management LLC (0.25%), Wedbush Securities Inc. (0.05%), Virtu Financial LLC (0.04%) and Barclays PLC (0.04%). Company insiders that own Aduro BioTech stock include Blaine Templeman, Celeste Ferber, Dirk G Brockstedt, Elsas Andrea Van, Gregory W Schafer, Jennifer Lew, Natalie Sacks and Stephen T Isaacs. View Institutional Ownership Trends for Aduro BioTech.

Which major investors are selling Aduro BioTech stock?

ADRO stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A. and Barclays PLC. Company insiders that have sold Aduro BioTech company stock in the last year include Celeste Ferber, Elsas Andrea Van, Jennifer Lew and Stephen T Isaacs. View Insider Buying and Selling for Aduro BioTech.

Which major investors are buying Aduro BioTech stock?

ADRO stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, State Street Corp, Wedbush Securities Inc. and Virtu Financial LLC. View Insider Buying and Selling for Aduro BioTech.

How do I buy shares of Aduro BioTech?

Shares of ADRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aduro BioTech's stock price today?

One share of ADRO stock can currently be purchased for approximately $1.12.

How big of a company is Aduro BioTech?

Aduro BioTech has a market capitalization of $90.17 million and generates $15.09 million in revenue each year. The biotechnology company earns $-95,360,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Aduro BioTech employs 152 workers across the globe.View Additional Information About Aduro BioTech.

What is Aduro BioTech's official website?

The official website for Aduro BioTech is http://www.aduro.com/.

How can I contact Aduro BioTech?

Aduro BioTech's mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company can be reached via phone at 510-848-4400 or via email at [email protected]


MarketBeat Community Rating for Aduro BioTech (NASDAQ ADRO)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  420 (Vote Outperform)
Underperform Votes:  241 (Vote Underperform)
Total Votes:  661
MarketBeat's community ratings are surveys of what our community members think about Aduro BioTech and other stocks. Vote "Outperform" if you believe ADRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Featured Article: Fiduciary

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel